eleven-valent pneumococcal tetanus-diphtheria toxoid conjugate vaccine

The eleven-valent pneumococcal tetanus-diphtheria toxoid conjugate vaccine (11-PncTD / 11PCV) is an investigational biologic vaccine developed by Sanofi Pasteur in collaboration with the ARIVAC Consortium. It contains Streptococcus pneumoniae capsular polysaccharides from 11 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F). Specifically, serotypes 1, 4, 5, 7F, 9V, 19F, and 23F are conjugated to tetanus toxoid, while serotypes 3, 6B, 14, and 18C are conjugated to diphtheria toxoid. The vaccine is designed to stimulate protective antibody responses against multiple pneumococcal serotypes to prevent pneumococcal pneumonia, invasive pneumococcal disease, pneumococcal sepsis, and pneumococcal meningitis in infants. A Phase III double-blind, placebo-controlled, randomized multicentre trial (ARIVAC study, ISRCTN62323832) was conducted in Bohol, Philippines (2000–2004) in approximately 12,000 infants, demonstrating efficacy against radiologically confirmed community-acquired pneumonia. The vaccine remained an investigational compound and was not commercialized.

Other names

eleven-valent pneumococcal conjugate vaccine11-valent pneumococcal conjugate vaccine11-valent pneumococcal tetanus-diphtheria toxoid conjugate vaccine11-valent pneumococcal tetanus-diphtheria toxoid-conjugated vaccine